NEW YORK (GenomeWeb News) – After years in development, a handheld point-of-care molecular diagnostic device from QuantuMDx is poised to hit the market next year with malaria and tuberculosis as its initial target markets, a company executive said last week on the sidelines of the 32nd Annual JP Morgan Healthcare Conference in San Francisco.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.